POMDOCTOR LIMITED Successfully Reinstates Compliance with Nasdaq Financial Standards

POMDOCTOR LIMITED Regains Nasdaq Compliance

POMDOCTOR LIMITED, a prominent player in the digital healthcare space, has made a significant stride by regaining compliance with Nasdaq’s bid price requirements. This development comes as part of the company's ongoing efforts to enhance its operations and ensure investor confidence. On July 10, 2026, Nasdaq notified POMDOCTOR that it successfully adhered to the minimum bid price rule of $1.00 per share, specifically outlined under Nasdaq Listing Rule 5450(a)(1).

Background

Earlier this year, POMDOCTOR faced challenges as the bid price for its American Depositary Shares (ADS) fell below the required threshold for over a month. According to an official notification received on January 29, 2026, the company’s shares were priced below $1.00 for 30 consecutive business days, which prompted the warning from Nasdaq. The management at POMDOCTOR recognized the urgency of addressing this issue promptly and began implementing strategic initiatives.

The Path to Compliance

Following proactive measures taken by the company, including engaging more deeply with their investor base and enhancing visibility in the market, POMDOCTOR saw a turnaround in its stock performance. From June 25 to July 9, 2026, the share price stabilized and surpassed the $1.00 mark consistently, leading to the reinstatement of compliance with Nasdaq’s requirements. This turnaround is seen as not just a regulatory win but a positive indicator of the company’s operational stability and growth potential.

Forward-Looking Operations

POMDOCTOR LIMITED is currently focused on expanding its AI-enabled healthcare solutions. The company aims to leverage advanced technologies and data analytics to enhance patient care. Their goal is to build a robust predictive healthcare infrastructure that incorporates insights from real-world healthcare data, promoting personalized treatment solutions. This ambitious plan is set to position POMDOCTOR as a leading entity in the healthcare innovation sector.

The company emphasizes the importance of maintaining robust relationships with both healthcare providers and technology partners as it moves forward. By advancing its capabilities, POMDOCTOR is poised to improve health outcomes while delivering long-lasting value to its stakeholders.

Conclusion

Regaining compliance with Nasdaq is a major achievement for POMDOCTOR LIMITED, reflecting their commitment to transparency and corporate governance. Investors and stakeholders can remain optimistic as the company continues to innovate within the healthcare technology space. As the market evolves, POMDOCTOR aims to not only meet compliance standards but also to exceed them while addressing the pressing needs of healthcare today.

For more information about POMDOCTOR LIMITED and its innovative healthcare solutions, visit the company's website at http://ir.7shiliu.com.